Screening of small molecule compounds that inhibits interaction between PD-1 and PD-L1
| Project/Area Number |
15K21235
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Drug development chemistry
Biological pharmacy
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
MATSUSHITA Yosuke 徳島大学, 先端酵素学研究所(プロテオ), 助教 (70634450)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 化合物スクリーニング / 免疫チェックポイント阻害剤 / 腫瘍免疫 / PD-1/PD-L1 |
|---|
| Outline of Final Research Achievements |
In recent years, immune checkpoint inhibitors that inhibit PD-1 / PD-L1 interaction have been approved as many cancer types and attracted attention as a new cancer therapy, but due to the characteristics of antibody, soaring drug prices Has begun to be seen as a problem. In this research, we promoted research aimed at searching for cheaper and lower molecular weight compounds with equivalent effect. Firstly, we narrowed down compounds by in silico screening using GPGPU, then established assay systems capable of quantifying the tumor activity of effector cells, and screened.
|
Report
(3 results)
Research Products
(2 results)
-
[Journal Article] Stapled BIG3 helical peptide ERAP extends potent antitumor activity for breast cancer therapeutics2017
Author(s)
Yoshimaru T, Aihara K, Komatsu M, Matsushita Y, Okazaki Y, Toyokuni S, Honda J, Sasa M, Miyoshi Y, Otaka A, Katagiri T
-
Journal Title
Scientific Reports
Volume: 印刷中
Related Report
Peer Reviewed / Open Access
-
